216
Participants
Start Date
October 31, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
TAK-385
TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
TAK-385
TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
TAK-385
TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
Placebo
TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
Chiba
Itchihara-shi
Matsuno-shi
Matsuyama
Nihama-shi
Fukui-shi
Fukuoka
Iizuka-shi
Yanagigawa-shi
Mebashi-shi
Ebetsu-shi
Sapporo
Amagasaki-shi
Kobe
Kamakura-shi
Yokohama
Ōita
Ibaraki-shi
Osaka
Sakai-shi
Tondabayashi-shi
Chuo-ku
Itabashi-ku
Setagaya-ku
Shinagawa-ku
Suginami-ku
Toyama
Lead Sponsor
Takeda
INDUSTRY